Suven Life Sciences witnessed a rise in share price on Tuesday after the company announces today that the grant of one product patent from Europe and one product patent from Israel corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029 respectively.

The granted claims of the patents are from the mechanism of action include the class of selective Alpha4Beta2 and H3 Inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.

Shares of Suven Life Sciences are trading at Rs 199.20, up Rs 5.05, or 2.60% at the Bombay Stock Exchange (BSE) on Tuesday at 10:27 a.m.